Kenya Oncology Therapeutics Market Analysis

Kenya Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Kenya Oncology Therapeutics Market will reach a value of $263 Mn from $127 Mn in 2022, growing at a CAGR of 9.5% during 2022-30.

Kenya is a lower middle-income, developing country in Eastern Africa bordering the Indian Ocean and Lake Victoria. Although progress has been made, such as the Cancer Action Plan, which was released in 2020, basic cancer care is still not where it should be for the majority of Kenyans. The Kenyan Network of Cancer Organizations (KENCO) is the national umbrella group for approximately 45 registered cancer civil society organisations scattered across the country that are working in various elements of cancer management in Kenya and are committed to a collaborative approach to cancer control. Cancer is the third biggest cause of mortality in Kenya, trailing only infectious and cardiovascular disorders.

The Cancer Prevention and Control Act, which establishes the National Cancer Institute to coordinate and govern cancer control activities in the country, is part of the regulatory framework.  In terms of reimbursement for oncology services, Kenya has a social health insurance scheme known as the National Hospital Insurance Fund (NHIF). Kenya's government spent 4.6% of its GDP on healthcare in 2020.

Market Dynamics

Market Growth Drivers Analysis

Cancer cases are increasing throughout Kenya's population. The International Agency for Research on Cancer (IARC) GLOBOCAN report for 2018 anticipated 47,887 new cancer cases per year, with 32,987 deaths. The Eldoret Cancer Registry (ECR) provides statistics and epidemiologic profiles for western Kenya. These aspects could boost Kenya's Oncology Therapeutics Market.

Market restraints

Cancer care is extremely expensive in Kenya, and many cancer patients are concerned about both their sickness and the cost of care. These cancer care inequalities can span multiple spectrums and transcend individual characteristics such as ethnicity, religion, gender, and socioeconomic background. They are exacerbated by a scarcity of cancer doctors, a scarcity of community-based cancer centres, low health insurance uptake, a complex health system, poverty and wealth index discrepancies, and climate change.

Despite the fact that tertiary public hospitals serve more than 80% of cancer patients in the country, almost all of whom are in Nairobi, patient volumes and a lack of modern cancer machines cause treatment interruption and long waiting times, resulting in distress as well as time and financial toxicity. Kenya has 0.2 radiation machines per 1,000 cancer patients. These factors may deter new entrants into the Kenya Oncology Therapeutics Market.

Competitive Landscape

Key Players

• Avenue Healthcare: This is a private healthcare provider that offers a range of services, including oncology. They provide cancer screening, diagnosis, and treatment options such as chemotherapy and radiation therapy
• The Nairobi Hospital: This is a leading private hospital in Kenya that offers comprehensive oncology services. They have a dedicated oncology centre that provides cancer screening, diagnosis, and treatment
• Aga Khan University Hospital: This is a private hospital that provides oncology services, including cancer screening, diagnosis, and treatment. They have a team of experienced oncologists who provide personalized treatment plans for each patient
• Cancer Care Kenya: This is a non-profit organization that provides cancer screening, diagnosis, and treatment services to underserved communities in Kenya. They work with a team of oncologists and healthcare providers to provide affordable and accessible cancer care
• Kenyatta National Hospital: This is the largest public hospital in Kenya and provides oncology services, including cancer screening, diagnosis, and treatment. They have a dedicated cancer centre that provides chemotherapy and radiation therapy

Recent Notable Updates

April 2023: Moderna, a renowned pharmaceutical company, stated that it is convinced that vaccinations for cancer, cardiovascular and autoimmune illnesses, and other conditions will be available in Kenya by 2030.

February 2023: In February 2023, the Kenyan government will organise the first-ever National Cancer Summit 2023, concluding in the commemoration of World Cancer Day. This reflects the need for a more coordinated and multi-sectoral response to Kenya's expanding cancer burden.

June 2022: Janssen Kenya, NHIF Sign an agreement to improve access to Prostrate Cancer Drugs. Following the signing of a joint Memorandum of Understanding (MoU) between NHIF and Johnson & Johnson Middle East FZ-LLC (Janssen Kenya), the prescription drug Abiraterone Acetate, which is used to treat advanced prostate cancer, will be made available to NHIF members as part of their current benefits package.

Healthcare Policies and Reimbursement Scenarios

The National Cancer Institute of Kenya was founded in accordance with the Cancer Prevention and Control Act No. 15 of 2012. In Kenya, oncology services are regulated by the Ministry of Health through the National Cancer Control Program (NCCP). The NCCP is responsible for policy formulation, planning, and implementation of cancer control programs, including oncology services. Health care is not publicly funded in Kenya. Most patients pay for health care through insurance schemes or via expensive out-of-pocket costs. According to the National Health Insurance Fund, the leading government-owned insurance company, only 25% of the Kenyan population is insured, not to mention the limited remittances of cancer treatment costs and bureaucratic pre-authorisation hoops.